Holen Sie sich die Stockscreener-App
7.90
2.35%
-0.19
Handel nachbörslich:
7.90
Schlusskurs vom Vortag:
$8.09
Offen:
$8.04
24-Stunden-Volumen:
294.73K
Relative Volume:
0.81
Marktkapitalisierung:
$486.55M
Einnahmen:
Nettoeinkommen (Verlust:
$-117.99M
KGV:
-3.6921
EPS:
-2.1397
Netto-Cashflow:
$-79.92M
1W Leistung:
+8.37%
1M Leistung:
-20.92%
6M Leistung:
-70.49%
1J Leistung:
-63.00%
1-Tages-Spanne:
$7.82
$8.07
1-Wochen-Bereich:
$7.15
$8.3099
52-Wochen-Spanne:
$7.11
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Firmenname
Oculis Holding Ag
Sektor
Branche
Telefon
-
Adresse
-
Compare OCS vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
7.90 | 486.55M | 0 | -117.99M | -79.92M | -2.1397 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-21 | Eingeleitet | Guggenheim | Buy |
| 2025-12-19 | Eingeleitet | JP Morgan | Overweight |
| 2025-08-27 | Eingeleitet | Needham | Buy |
| 2023-12-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-10-05 | Eingeleitet | Stifel | Buy |
| 2023-06-14 | Eingeleitet | BofA Securities | Buy |
| 2023-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-06-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-10 | Eingeleitet | Pareto | Buy |
| 2023-04-28 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
Oculis kynnir ný lífmerkisgögn (e. Biomarker Data) úr fasa 2 ACUITY-rannsókninni sem styðja enn frekar taugaverndandi möguleika Privosegtor við sjóntaugabólgu - GlobeNewswire Inc.
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis - GlobeNewswire Inc.
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting - GlobeNewswire Inc.
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki - GlobeNewswire Inc.
Oculis Holding AG Warrants (OCSAW) Advance 6.92% Toward Key ResistanceValue Area Low - https://www.dars.gov.et/
Oculis Holding AG (OCS) Slips 3.70% to $8.34 as Shares Drift Toward Lower SupportMA Crossover - https://www.dars.gov.et/
Oculis Holding (NasdaqGM:OCS) Stock Forecast & Analyst Predictions - Simply Wall Street
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day - GlobeNewswire Inc.
Oculis Holding AG (OCS) stock price, news, quote and history - Yahoo Finance UK
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength? - Zacks Investment Research
A board member bought Oculis shares - Stock Titan
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Yahoo Finance UK
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Yahoo Finance
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade - qz.com
Precision Trading with Oculis Holding Ag (OCS) Risk Zones - Stock Traders Daily
Oculis doses first patient in phase 3 privosegtor trial for ON - Glance by Eyes On Eyecare
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.79 as Consolidation ContinuesBuffered ETF - careplusvn.com
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.79 as Consolidation ContinuesGap Down Bounce Plays - www.dars.gov.et
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade - Yahoo Finance
Oculis Holding - The Pharma Letter
H.C. Wainwright reiterates Oculis stock rating on trial start - Investing.com
Oculis Holding AG Ordinary shares (NASDAQ: OCS) Share Price, OCS Stock News, OCS Share Price & Updates - kalkine.ca
Oculis Holding AG Ordinary shares (NASDAQ: OCS) Share Price, OCS Stock News, OCS Share Price & Updates - Kalkine
There Is No Approved Specific Treatment for Acute Optic Neuritis. Oculis Is Testing One. - stocktitan.net
Enterprise value to revenue forward of Oculis Holding AG – FWB:CR5 - TradingView
Oculis (OCS) Earnings Reading: EPS Lands Above Forecast in the Latest Session; Post-Report: The Share Price Adds 2.88% at the CloseReturn On Capital - dars.gov.et
Oculis (OCS) Daily Review: Rises 0.38% to $13.19 at the Close; Chart Reference: $12.53 and $13.85 Define the Nearby Reference Levels for the Current SessionAnchored VWAP - vinanet.vn
Oculis (OCSAW) Session-Level Review: Ends Up by 6.00% at $5.04 in the Latest Session; Current Setup: the Near-Term Reference Band Stretches From $4.79 to $5.29 in the Current UpdateAggressive Growth Picks - vinanet.vn
Oculis (OCS) Daily Review: Rises 0.38% to $13.19 at the Close; Chart Reference: $12.53 and $13.85 Define the Nearby Reference Levels for the Current SessionATR Trailing Stop - careplusvn.com
Oculis (OCS) Latest Earnings Reading: EPS Exceeds Its Estimate in the Latest Reading; Share Response: Shares Move 0.38% Up at the CloseSlow Growth Warning - dars.gov.et
Oculis (OCS) Latest Earnings Reading: EPS Exceeds Its Estimate in the Latest Reading; Share Response: Shares Move 0.38% Up at the CloseEarnings Call Transcript - dars.gov.et
Oculis (OCS) Latest Earnings Reading: EPS Exceeds Its Estimate in the Latest Reading; Share Response: Shares Move 0.38% Up at the CloseRevenue Estimate Trend - dars.gov.et
Oculis Holding (OCS) Advances 0.94% as Shares Hold Above Key SupportDouble Top - vinanet.vn
Oculis Holding (OCS) Advances 0.94% as Shares Hold Above Key SupportVolume Dry Up - siam.in
Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com Nigeria
The Technical Signals Behind (OCS) That Institutions Follow - Stock Traders Daily
Four Oculis directors' restricted stock units vest in Aug. 13 notifications - Stock Titan
Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Zacks Investment Research
Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com South Africa
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Yahoo Finance
Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com Australia
Stifel reiterates Buy rating on Oculis stock, $40 target - Investing.com
Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com India
Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on Oculis stock, $40 target - Investing.com
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.50 as Consolidation Range NarrowsVolatility Breakout Picks - Vinanet
Oculis buys out privosegtor’s global rights from Accure - Glance by Eyes On Eyecare
Finanzdaten der Oculis Holding Ag-Aktie (OCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oculis Holding Ag-Aktie (OCS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CHRISTINA ACKERMANN | Director |
Oct 09 '25 |
Proposed Sale |
19.87 |
7,460 |
148,230 |
0 |
| Sherif Riad | Officer |
Proposed Sale |
17.70 |
25,000 |
442,500 |
0 |
3.09%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):